凋亡抑制蛋白Survivin在DLBCL中的表达及其临床意义

Expression of Survivin and Its Significance in Diffuse Large B-Cell Lymphoma

目的探讨凋亡抑制蛋白Survivin在弥漫大B细胞淋巴瘤(DLBCL)中的表达情况及其临床意义。方法采用免疫组织化学SP法,检测Survivin在84例DLBCL及20例淋巴结反应性增生(RH)中的表达水平。结果 Survivin蛋白在DLBCL中的表达率64.3%(54/84)明显高于RH的0.0%(0/20),两者差异有统计学意义(P<0.01);Survivin在DLBCL中的表达与患者年龄、性别、首发部位、临床分期、IPI分级、血清LDH水平、结外病灶数目无关(P>0.05);Survivin蛋白表达的DLBCL患者的平均生存时间(49个月)明显短于无表达的患者(60个月)。结论 Survivin蛋白参与DLBCL的发生发展,是判断预后极有价值的参考依据。

Objective To investigate the expression of Survivin and its significance in diffuse large Bcell lymphoma. Methods The SP immunohistochemistry staining method was used to detect the expression of Survivin. Results Survivin was positive in 54 of 84 （64.3%） cases of diffuse large B-cell lymphoma, and its positive rate was higher than that of reactive hyperplasia of the lymph node（P 〈0.01 ）. The expression of Survivin was irrelevant to age, gender, initial organ, clinical stage, serum LDH level, IPI grade and extranodal extension of diffuse large B-cell lymphoma（ P 〉 0.05）. The mean survival period of patients with Survivin positive expression was significantly shortened as compared with the Survivin negative group. Conclusion Survivin plays certain roles in the oncogenesis and the progression of diffuse large B-cell lymphoma, and it is useful prognostic index.